BSPM [Biostar Pharmaceuticals,] S-8: FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT

[FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biostar Pharmaceuticals, Inc. Maryland (State or other jurisdiction of incorporation or organization) 20-5101287 (I.R.S. Employer Identification No.) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 including zip code) (Full title of the plan) Ronghua Wang President and Chief Executive Officer No. 588 Shiji Xi Avenue] [Biostar Pharmaceuticals, Inc. 2011 Stock Option Compensation Plan This Biostar Pharmaceuticals, Inc. 2011 Stock Option Compensation Plan Plan 1. Definitions. (a) Board " (b) Code " (c) Committee Rule 16b-3 Exchange Act " (d) Company " (e) Exchange Act " (f) Fair Market Value " (g) Grant " (h) Grant Agreement " (i) Maryland Securities Rules " (j) Option Optionee] [[Cozen O’Connor Letterhead] August 16, 2012 Biostar Pharmaceuticals, Inc. No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 Re: Registration Statement on Form S-8 Very truly yours, EX-5 3 ex5-1.htm] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 of Biostar Pharmaceuticals, Inc. of our report dated March 27, 2012 relating to the consolidation financial statements, which appears in the Annual Report on Form 10-K of Biostar Pharmaceuticals,]

By | 2016-03-03T11:50:18+00:00 August 17th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] S-8: FORMS-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF

[FORMS-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biostar Pharmaceuticals, Maryland (State or other jurisdiction oforporation or organization) 20-5101287 (I.R.S. Employer Identification No.) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China 712046luding zipde) (Full title of the plan) Ronghua Wang President and Chief Executive Officer] [Biostar Pharmaceuticals, 2011 Stock Optionmpensation Plan This Biostar Pharmaceuticals, 2011 Stock Optionmpensation Plan Plan 1. Definitions. (a) Board " (b)de " (c)mmittee Rule 16b-3 Exchange Act " (d)mpany " (e) Exchange Act " (f) Fair Market Value " (g) Grant " (h) Grantreement] [[Cozen OConnor Letterhead] August 16, 2012 Biostar Pharmaceuticals, No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China 712046 Re: Registration Statement on Form S-8 Very truly yours, ex5-1.htm 3 EX-5] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors of Biostar Pharmaceuticals, We herebynsent to theorporation by reference in the Registration Statement on Form S-8of Biostar Pharmaceuticals, of our reportted March 27, 2012 relating to thensolidation financial statements, which appears in the Annual Report on Form 10-K of Biostar Pharmaceuticals, for the]

By | 2016-02-07T15:43:26+00:00 August 17th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x June 30, 2012 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm]

By | 2016-03-03T11:52:28+00:00 August 14th, 2012|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: FORM 10-Q (Mark One) x June 30, 2012

[FORM 10-Q (Mark One) x June 30, 2012 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm]

By | 2016-03-03T11:53:19+00:00 August 14th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x June 30, 2012 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Ronghua Wang Chief Executive Officer ex32-1.htm 4 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) ex32-2.htm 5 EX-32.2]

By | 2016-02-07T15:45:04+00:00 August 14th, 2012|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: FORM 10-Q (Mark One) x June 30, 2012

[FORM 10-Q (Mark One) x June 30, 2012 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Ronghua Wang Chief Executive Officer ex32-1.htm 4 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) ex32-2.htm 5 EX-32.2]

By | 2016-02-07T15:45:38+00:00 August 14th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[BIOSTAR PHARMACEUTICALS, INC. RECEIVES APPROVAL FROM XIANYANG SFDA TO RESTART SALES OF ITS GEL CAPSULE DRUGS XIANYANG, China, August 3, 2012 - Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that on July 30, 2012, after]

By | 2016-03-03T11:54:18+00:00 August 6th, 2012|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: BIOSTAR PHARMACEUTICALS, INC. RECEIVES APPROVAL FROM XIANYANG SFDA

[BIOSTAR PHARMACEUTICALS, INC. RECEIVES APPROVAL FROM XIANYANG SFDA TO RESTART SALES OF ITS GEL CAPSULE DRUGS XIANYANG, China, August 3, 2012 - Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that on July 30, 2012, after]

By | 2016-03-03T11:56:01+00:00 August 6th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: BIOSTAR PHARMACEUTICALS, RECEIVES APPROVAL FROM XIANYANG SFDA TO

[BIOSTAR PHARMACEUTICALS, RECEIVES APPROVAL FROM XIANYANG SFDA TO RESTARTLES OF ITS GELPSULE DRUGS XIANYANG, China, August 3, 2012 - Biostar Pharmaceuticals, (NASDAQ GM: BSPM) ("Biostar" or "thempany"), a-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases andnditions, today announced that on July 30, 2012, after a thorough]

By | 2016-02-07T15:47:24+00:00 August 6th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[BIOSTAR PHARMACEUTICALS, RECEIVES APPROVAL FROM XIANYANG SFDA TO RESTARTLES OF ITS GELPSULE DRUGS XIANYANG, China, August 3, 2012 - Biostar Pharmaceuticals, (NASDAQ GM: BSPM) ("Biostar" or "thempany"), a-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases andnditions, today announced that on July 30, 2012, after a thorough]

By | 2016-02-07T15:46:31+00:00 August 6th, 2012|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Skip to toolbar